Trudhesa (Dihydroergotamine Mesylate) Patent Expiration, LOE Window & CMS Spending

Trudhesa (Dihydroergotamine Mesylate) by Impel: FDA Orange Book LOE 2039-01-04, 4 AB generics, $5.9M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorImpel
FDA Application & PathwayN213436 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2039-01-04
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors4
2024 CMS Total Public Spend$5.9M
2024 Medicare Part D Spend$5.6M
2024 Medicaid Spend$289K
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel